Skip to main content
. 2016 Mar 18;7(17):23715–23729. doi: 10.18632/oncotarget.8173

Figure 3. Activated ALK and downstream signaling is preserved in the novel ALK-fusion mutations, R1192P and T1151M.

Figure 3

Immunoblotting for ALK and downstream signaling targets at the indicated concentrations of six ALK TKIs for FL5.12 cells (A), FL5.12 cells infected with an MSCV-based vector co-expressing GFP and wild-type NPM-ALK (B), NPM-ALK R1192P (C) or NPM-ALK T1151M (D).